Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.49 |
| ▸ | JAK3 | P52333 | 11/20 | 0.49 |
| ▸ | LCK | P06239 | 8/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18296116 | 0.85 | BTK (0.54) | BTKJAK3LCKEGFR | |
| SCHEMBL18884506 | 0.81 | BTK (0.71) | BTKJAK3LCKEGFR | |
| SCHEMBL23081162 | 0.78 | BTK (0.47) | BTKJAK3LCKEGFR | |
| SCHEMBL18296401 | 0.77 | LCK (0.65) | BTKJAK3LCKEGFR | |
| SCHEMBL18884514 | 0.77 | BTK (0.70) | BTKJAK3LCKEGFR | |
| SCHEMBL19824667 | 0.77 | JAK3 (0.68) | BTKJAK3LCKEGFR | |
| SCHEMBL20867957 | 0.77 | JAK3 (0.71) | BTKJAK3LCKEGFR | |
| SCHEMBL21946329 | 0.76 | JAK3 (0.60) | BTKJAK3LCKEGFR | |
| SCHEMBL18884581 | 0.76 | BTK (0.66) | BTKJAK3LCKEGFR | |
| SCHEMBL18283520 | 0.76 | JAK3 (0.63) | BTKJAK3LCKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | BTK 1/4885JAK3 64/4885LCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.